Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention
- 1 March 2020
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 13 (3), 229-240
- https://doi.org/10.1158/1940-6207.capr-19-0316
Abstract
The discovery of aberrant crypt foci (ACF) more than three decades ago not only enhanced our understanding of how colorectal tumors form, but provided new opportunities to detect lesions prior to adenoma development and intervene in the colorectal carcinogenesis process even earlier. Because not all ACF progress to neoplasia, it is important to stratify these lesions based on the presence of dysplasia and establish early detection methods and interventions that specifically target dysplastic ACF (microadenomas). Significant progress has been made in characterizing the morphology and genetics of dysplastic ACF in both preclinical models and humans. Image-based methods have been established and new techniques that utilize bioactivatable probes and capture histologic abnormalities in vivo are emerging for lesion detection. Successful identification of agents that target dysplastic ACF holds great promise for intervening even earlier in the carcinogenesis process to maximize tumor inhibition. Future preclinical and clinical prevention studies should give significant attention to assessing the utility of dysplastic ACF as the earliest identifiable biomarker of colorectal neoplasia and response to therapy. See all articles in this Special Collection Honoring Paul F. Engstrom, MD, Champion of Cancer PreventionKeywords
This publication has 110 references indexed in Scilit:
- Ability of a novel blue laser imaging system for the diagnosis of colorectal polypsDigestive Endoscopy, 2013
- Short curcumin treatment modulates oxidative stress, arginase activity, aberrant crypt foci, and TGF-β1 and HES-1 transcripts in 1,2-dimethylhydrazine-colon carcinogenesis in miceToxicology, 2012
- Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer ChemopreventionCancer Prevention Research, 2011
- R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesisOncology Reports, 2010
- Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinaseMolecular Carcinogenesis, 2010
- A Multicenter Study of Prevalence and Risk Factors for Aberrant Crypt FociClinical Gastroenterology and Hepatology, 2009
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasThe New England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerThe New England Journal of Medicine, 2003
- CpG Island Methylation in Aberrant Crypt Foci of the ColorectumThe American Journal of Pathology, 2002
- Comparative effects of secondary bile acids, deoxycholic and lithocholic acids, on aberrant crypt foci growth in the postinitiation phases of colon carcinogenesisNutrition and Cancer, 1998